ArticleJournal of medical case reports2026
Effectiveness of neoadjuvant chemotherapy with lenvatinib plus pembrolizumab in advanced endometrial cancer: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA combination of lenvatinib and pembrolizumab is a viable treatment option for unresectable advanced endometrial cancer after platinum-based chemotherapy; however, its efficacy as neoadjuvant chemotherapy remains to be elucidated. CASE PRESENTATION: The patient was a 51-year-old Japanese woman with severe anemia and suspected endometrial cancer based on magnetic resonance imaging. Adenocarcinoma was detected in the endometrium and diagnosed as stage IVB (T3aN2M1) endometrial cancer. Hysterectomy was considered difficult; therefore, paclitaxel plus carboplatin was administered as neoadjuvant chemotherapy. During treatment, the patient experienced massive genital bleeding, which necessitated uterine artery embolization and blood transfusion. Following these interventions, the bleeding was drastically reduced, enabling the administration of five cycles of lenvatinib plus pembrolizumab. The tumor markedly shrank, allowing surgery to be performed. The removed uterus exhibited induration but no residual cancer.
conclusionLenvatinib plus pembrolizumab may represent a feasible neoadjuvant option for achieving tumor regression and enabling surgical resection with a pathological complete response in advanced endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.